Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

NCT04323202 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Basal Cell Carcinoma of the Head and Neck

Interventions

DRUG: Pembrolizumab
OTHER: Tissue collection

Sponsor

Case Comprehensive Cancer Center